Relationship Between the Response to Antibody Therapy and Symptoms of Depression and Anxiety Disorders in Patients with Severe Asthma

References

• Reddel HK, Boulet L-P, Bateman ED. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Am J Respir Crit Care Med. 2022;205(1):17–35. doi:10.1164/rccm.202109-2205PP
   PubMed Web of Science ®Google Scholar
• Alonso J, de Jonge P, Lim CCW, et al. Association between mental disorders and subsequent adult onset asthma. J Psychiatr Res. 2014;59:179–188. doi:10.1016/j.jpsychires.2014.09.007
   PubMed Web of Science ®Google Scholar
• Baumeister H, Balke K, Härter M. Psychiatric and somatic comorbidities are negatively associated with quality of life in physically ill patients. J Clin Epidemiol. 2005;58(11):1090–1100. doi:10.1016/j.jclinepi.2005.03.011
   PubMed Web of Science ®Google Scholar
• Calam R, Gregg L, Simpson B, et al. Childhood asthma, behavior problems, and family functioning. J Allergy Clin Immunol. 2003;112(3):499–504. doi:10.1016/S0091-6749(03)01606-3
   PubMed Web of Science ®Google Scholar
• Goodwin RD, Jacobi F, Thefeld W. Mental disorders and asthma in the community. Arch Gen Psychiatry. 2003;60(11):1125–1130. doi:10.1001/archpsyc.60.11.1125
   PubMed Web of Science ®Google Scholar
• Katon W, Lozano P, Russo J, et al. The prevalence of DSM-IV anxiety and depressive disorders in youth with asthma compared with controls. J Adolesc Health. 2007;41(5):455–463. doi:10.1016/j.jadohealth.2007.05.023
   PubMed Web of Science ®Google Scholar
• Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res. 2002;53(4):849–857. doi:10.1016/S0022-3999(02)00304-5
   PubMed Web of Science ®Google Scholar
• DGPPN B, KBV A, Akdä B, et al. S3-Leitlinie/Nationale versorgungsleitlinie unipolare depression. Auflage. 2015;5:2015.
   Google Scholar
• Gautam S, Jain A, Gautam M, et al. Clinical Practice Guidelines for the Management of Generalised Anxiety Disorder (GAD) and Panic Disorder (PD). Indian J Psychiatry. 2017;59(Suppl 1):S67–s73. doi:10.4103/0019-5545.196975
   PubMedGoogle Scholar
• Agache I, Rocha C, Beltran J, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1043–1057. doi:10.1111/all.14235
   PubMed Web of Science ®Google Scholar
• Gallo S, Castelnuovo P, Spirito L, et al. Mepolizumab improves outcomes of chronic rhinosinusitis with nasal polyps in severe asthmatic patients: a multicentric real-life study. J Pers Med. 2022;12:8.
   Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984. doi:10.1056/NEJMoa0808991
   PubMed Web of Science ®Google Scholar
• Patella V, Pelaia C, Zunno R, et al. Biologicals decrease psychological distress, anxiety and depression in severe asthma, despite Covid-19 pandemic. Respir Med. 2022;200:106916. doi:10.1016/j.rmed.2022.106916
   PubMed Web of Science ®Google Scholar
• Fong WCG, Azim A, Knight D, et al. Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes. Clin Exp Allergy. 2021;51(8):1019–1032. doi:10.1111/cea.13882
   PubMed Web of Science ®Google Scholar
• Drick N, Milger K, Seeliger B, et al. Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma. J Asthma Allergy. 2020;13:605–614. doi:10.2147/JAA.S270298
   PubMed Web of Science ®Google Scholar
• Drick N, Seeliger B, Welte T, et al. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response. BMC Pulm Med. 2018;18(1):119. doi:10.1186/s12890-018-0689-2
   PubMed Web of Science ®Google Scholar
• Kayser MZ, Drick N, Milger K, et al. Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months. J Asthma Allergy. 2021;14:863–871. doi:10.2147/JAA.S319572
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. doi:10.1183/13993003.00588-2019
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Maisto SA, McNeil M, et al. Three questions can detect hazardous drinkers. J Fam Pract. 2001;50(4):313–320.
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi:10.1111/j.1600-0447.1983.tb09716.x
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JBW, et al. The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry. 2010;32(4):345–359. doi:10.1016/j.genhosppsych.2010.03.006
   PubMed Web of Science ®Google Scholar
• Snaith RP, Zigmond AS. The Hospital Anxiety and Depression Scale. Br Med J. 1986;292(6516):344. doi:10.1136/bmj.292.6516.344
   PubMed Web of Science ®Google Scholar
• Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59–65. doi:10.1016/j.jaci.2003.09.008
   PubMed Web of Science ®Google Scholar
• Spigel D, De Marinis F, Giaccone G, et al. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208. doi:10.1016/0168-8510(90)90421-9
   PubMed Web of Science ®Google Scholar
• Milger K, Korn S, Feder C, et al. Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS) [Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS)]. Pneumologie. 2023;2023:1. German.
   Google Scholar
• Jacobi F, Höfler M, Strehle J, et al. Psychische Störungen in der Allgemeinbevölkerung. Studie zur Gesundheit Erwachsener in Deutschland und ihr Zusatzmodul „Psychische Gesundheit (DEGS1-MH) [Mental disorders in the general population: study on the health of adults in Germany and the additional module mental health (DEGS1-MH)]. Nervenarzt. 2014;85(1):77–87. German. doi:10.1007/s00115-013-3961-y
   PubMedGoogle Scholar
• Chen MH, Su T-P, Chen Y-S, et al. Higher risk of developing major depression and bipolar disorder in later life among adolescents with asthma: a nationwide prospective study. J Psychiatr Res. 2014;49:25–30. doi:10.1016/j.jpsychires.2013.10.015
   PubMed Web of Science ®Google Scholar
• Dering MR, Lepsy N, Fuge J, et al. Prevalence of mental disorders in patients with chronic thromboembolic pulmonary hypertension. Front Psychiatry. 2022;13:821466. doi:10.3389/fpsyt.2022.821466
   PubMed Web of Science ®Google Scholar
• Olsson KM, Meltendorf T, Fuge J, et al. Prevalence of mental disorders and impact on quality of life in patients with pulmonary arterial hypertension. Front Psychiatry. 2021;12:667602. doi:10.3389/fpsyt.2021.667602
   PubMed Web of Science ®Google Scholar
• Zhang MW, Ho RCM, Cheung MWL, et al. Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry. 2011;33(3):217–223. doi:10.1016/j.genhosppsych.2011.03.009
   PubMed Web of Science ®Google Scholar
• Willgoss TG, Yohannes AM. Anxiety disorders in patients with COPD: a systematic review. Respir Care. 2013;58(5):858–866. doi:10.4187/respcare.01862
   PubMed Web of Science ®Google Scholar
• Matcham F, Davies R, Hotopf M, et al. The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for Rheumatology Biologics Register. Rheumatology. 2018;57(5):835–843. doi:10.1093/rheumatology/kex528
   PubMed Web of Science ®Google Scholar
• Michelsen B, Kristianslund EK, Sexton J, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2017;76(11):1906–1910. doi:10.1136/annrheumdis-2017-211284
   PubMed Web of Science ®Google Scholar
• Rathbun AM, Harrold LR, Reed GW. A prospective evaluation of the effects of prevalent depressive symptoms on disease activity in rheumatoid arthritis patients treated with biologic response modifiers. Clin Ther. 2016;38(7):1759–1772.e3. doi:10.1016/j.clinthera.2016.06.007
   PubMed Web of Science ®Google Scholar
• Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med. 2000;160(21):3278–3285. doi:10.1001/archinte.160.21.3278
   PubMed Web of Science ®Google Scholar
• Tarrants M, Oleen-Burkey M, Castelli-Haley J, et al. The impact of comorbid depression on adherence to therapy for multiple sclerosis. Mult Scler Int. 2011;2011:271321. doi:10.1155/2011/271321
   PubMedGoogle Scholar
• Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–457. doi:10.1016/j.biopsych.2009.09.033
   PubMed Web of Science ®Google Scholar
• Oyamada HAA, Cafasso MOSD, Vollmer CM, et al. Major depressive disorder enhances Th2 and Th17 cytokines in patients suffering from allergic Rhinitis and Asthma. Int Arch Allergy Immunol. 2021;182(12):1155–1168. doi:10.1159/000517478
   PubMedGoogle Scholar
• Kharaba Z, Feghali E, El Husseini F, et al. An assessment of quality of life in patients with Asthma through physical, emotional, social, and occupational Aspects. A cross-sectional study. Front Public Health. 2022;10:883784. doi:10.3389/fpubh.2022.883784
   PubMed Web of Science ®Google Scholar
• Yohannes AM. Management of anxiety and depression in patients with COPD. Expert Rev Respir Med. 2008;2(3):337–347. doi:10.1586/17476348.2.3.337
   PubMedGoogle Scholar
• Smoller JW, Pollack MH, Otto MW, et al. Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. Am J Respir Crit Care Med. 1996;154(1):6–17. doi:10.1164/ajrccm.154.1.8680700
   PubMed Web of Science ®Google Scholar
• McCarron RM, Shapiro B, Rawles J, et al. Depression. Ann Intern Med. 2021;174(5):Itc65–itc80. doi:10.7326/AITC202105180
   PubMed Web of Science ®Google Scholar
• DeMartini J, Patel G, Fancher TL. Generalized Anxiety Disorder. Ann Intern Med. 2019;170(7):Itc49–itc64. doi:10.7326/AITC201904020
   PubMed Web of Science ®Google Scholar
• Yohannes AM, Willgoss TG, Baldwin RC, et al. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry. 2010;25(12):1209–1221. doi:10.1002/gps.2463
   PubMed Web of Science ®Google Scholar
• Russell RJ, Brightling C. Pathogenesis of asthma: implications for precision medicine. Clin Sci. 2017;131(14):1723–1735. doi:10.1042/CS20160253
   PubMed Web of Science ®Google Scholar
• DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101–2107. doi:10.1001/archinte.160.14.2101
   PubMed Web of Science ®Google Scholar